本文選題：結(jié)節(jié)性硬化癥 + 面部血管纖維瘤　； 參考：《首都醫(yī)科大學(xué)學(xué)報》2017年05期

【摘要】：結(jié)節(jié)性硬化癥是一種常染色體顯性遺傳的神經(jīng)皮膚綜合征,引起多器官錯構(gòu)瘤。60%的病人伴面部血管纖維瘤,嚴(yán)重時可致毀容。口服哺乳動物西羅莫司靶蛋白(mammalian target of rapamycin,m TOR)抑制劑如西羅莫司可治療結(jié)節(jié)性硬化相關(guān)癥狀,提出外用西羅莫司治療面部血管纖維瘤效果較好,本文就西羅莫司的作用機(jī)制、臨床治療效果、不良反應(yīng)做一綜述。
[Abstract]:Nodular sclerosis is an autosomal dominant neurocutaneous syndrome, causing multiple organ hamartoma .60% of patients with facial angiofibroma. Oral sirolimus target protein (mammalian target of rapamycinom TOR inhibitor such as sirolimus can treat nodular sclerosis-related symptoms. It is suggested that sirolimus is effective in the treatment of facial angiofibroma. The clinical therapeutic effect and adverse reaction were summarized.
【作者單位】： 首都醫(yī)科大學(xué)宣武醫(yī)院皮膚性病科;
【分類號】：R596;R732.2
，

本文編號：2086437